Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy

Hiroko Matsuura; Takashi Murakami; Kazuyoshi Hina; Keizo Yamamoto; Hiroshi Kawamura; Taiji Sogo; Ryoko Shinohata; Shinichi Usui; Yoshifumi Ninomiya; Shozo Kusachi

doi:10.1016/j.clinbiochem.2007.10.015

Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy

Hiroko Matsuura, Takashi Murakami, Kazuyoshi Hina, Keizo Yamamoto, Hiroshi Kawamura, Taiji Sogo, Ryoko Shinohata, Shinichi Usui, Yoshifumi Ninomiya, Shozo Kusachi

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p < 0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p < 0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

Original language	English
Pages (from-to)	134-139
Number of pages	6
Journal	Clinical Biochemistry
Volume	41
Issue number	3
DOIs	https://doi.org/10.1016/j.clinbiochem.2007.10.015
Publication status	Published - Feb 2008

Keywords

Cardiomyopathy
Clinical study
Enzyme immunoassay
Peptide
Sensitivity and specificity
Tachyarrhythmia

ASJC Scopus subject areas

Clinical Biochemistry

Access to Document

10.1016/j.clinbiochem.2007.10.015

Fingerprint Dive into the research topics of 'Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy'. Together they form a unique fingerprint.

Cite this

Matsuura, H., Murakami, T., Hina, K., Yamamoto, K., Kawamura, H., Sogo, T., Shinohata, R., Usui, S., Ninomiya, Y., & Kusachi, S. (2008). Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. Clinical Biochemistry, 41(3), 134-139. https://doi.org/10.1016/j.clinbiochem.2007.10.015

Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. / Matsuura, Hiroko; Murakami, Takashi; Hina, Kazuyoshi; Yamamoto, Keizo; Kawamura, Hiroshi; Sogo, Taiji; Shinohata, Ryoko ; Usui, Shinichi; Ninomiya, Yoshifumi; Kusachi, Shozo.

In: Clinical Biochemistry, Vol. 41, No. 3, 02.2008, p. 134-139.

Research output: Contribution to journal › Article › peer-review

Matsuura, H, Murakami, T, Hina, K, Yamamoto, K, Kawamura, H, Sogo, T, Shinohata, R , Usui, S, Ninomiya, Y & Kusachi, S 2008, 'Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy', Clinical Biochemistry, vol. 41, no. 3, pp. 134-139. https://doi.org/10.1016/j.clinbiochem.2007.10.015

Matsuura, Hiroko ; Murakami, Takashi ; Hina, Kazuyoshi ; Yamamoto, Keizo ; Kawamura, Hiroshi ; Sogo, Taiji ; Shinohata, Ryoko ; Usui, Shinichi ; Ninomiya, Yoshifumi ; Kusachi, Shozo. / Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy. In: Clinical Biochemistry. 2008 ; Vol. 41, No. 3. pp. 134-139.

@article{baaa5a1c8c96481f9fdee493119aec17,

title = "Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy",

abstract = "Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p < 0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p < 0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.",

keywords = "Cardiomyopathy, Clinical study, Enzyme immunoassay, Peptide, Sensitivity and specificity, Tachyarrhythmia",

author = "Hiroko Matsuura and Takashi Murakami and Kazuyoshi Hina and Keizo Yamamoto and Hiroshi Kawamura and Taiji Sogo and Ryoko Shinohata and Shinichi Usui and Yoshifumi Ninomiya and Shozo Kusachi",

year = "2008",

month = feb,

doi = "10.1016/j.clinbiochem.2007.10.015",

language = "English",

volume = "41",

pages = "134--139",

journal = "Clinical Biochemistry",

issn = "0009-9120",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Association of elevated plasma B-type natriuretic peptide levels with paroxysmal atrial fibrillation in patients with nonobstructive hypertrophic cardiomyopathy

AU - Matsuura, Hiroko

AU - Murakami, Takashi

AU - Hina, Kazuyoshi

AU - Yamamoto, Keizo

AU - Kawamura, Hiroshi

AU - Sogo, Taiji

AU - Shinohata, Ryoko

AU - Usui, Shinichi

AU - Ninomiya, Yoshifumi

AU - Kusachi, Shozo

PY - 2008/2

Y1 - 2008/2

N2 - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p < 0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p < 0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

AB - Objectives: To investigate the relationship between the plasma B-type natriuretic peptide (BNP) level and the occurrence of atrial fibrillation (AF) in nonobstructive hypertrophic cardiomyopathy (HCM) patients. Methods: Patients (n = 97) were classified into chronic AF (CAF; n = 14), paroxysmal AF (PAF; n = 18) and normal sinus rhythm (NSR; n = 65) groups. The plasma BNP values were analyzed with logarithmic transformation. Results: The PAF group showed significantly higher plasma BNP levels than the NSR group [mean (range; - l SD and + 1 SD); 248.3 (143.5, 429.5) vs. 78.2 (27.9, 218.8 ng/L), p < 0.0001]. The CAF group also showed significantly higher plasma BNP levels than the NSR group [291.1 (161.4, 524.8 ng/L), p < 0.0001]. Multivariate analysis with other clinical factors selected association of PAF as one of the factors that increased the plasma BNP level. Conclusions: The present study indicated that plasma BNP level is clinically useful for identification of nonobstructive HCM patients who have a risk of PAF.

KW - Cardiomyopathy

KW - Clinical study

KW - Enzyme immunoassay

KW - Peptide

KW - Sensitivity and specificity

KW - Tachyarrhythmia

UR - http://www.scopus.com/inward/record.url?scp=38849146408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849146408&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2007.10.015

DO - 10.1016/j.clinbiochem.2007.10.015

M3 - Article

C2 - 18039472

AN - SCOPUS:38849146408

VL - 41

SP - 134

EP - 139

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 3

ER -